• E I Prokopenko, E O Shcherbakova, A V Vatazin, E E Kruglov, S A Pasov, N E Budnikova, S G Agafonova, and E V Rusanova.
• Terapevt Arkh. 2005 Jan 1; 77 (1): 67-72.

AimTo study infectious complications in renal transplant recipients receiving mycophenolate mofetil (MMF) for prevention of acute transplant rejection or treatment of chronic allograft nephropathy (CAN).Material And MethodsA group of renal transplant recipients (n=47) receiving 1.0-2.0 g/day MMF with cyclosporine A (CsA) and steroids as maintaining immunosuppression was compared to a group (n=47) taking triple immunosuppressive therapy which included azathioprine (Aza). Separate group of patients (n=9) received MMF for treatment of CAN. In all groups etiology and incidence of infections were evaluated.ResultsDuring 2 years various posttransplant infections developed in 72.3% patients on MMF and 93.6% on Aza. The incidence of viral infections was 53.2% in MMF and 59.6% in Aza group, the incidence of bacterial infection--55.3 and 70.2%, respectively. Among 9 recipients with CAN the infections occurred in five. There were two cases of active tuberculosis in Aza group, one--in MMF group and one in patients with CAN.ConclusionWe suggest that MMF in the dose 1-2 g/day does not increase infection rates in renal transplant recipients comparing Aza.

24 keywords...

hide…